- The key vendors in the infectious diseases market in the US 2015-2019 are F. Hoffmann-La Roche Ltd., Gilead Sciences Inc., GlaxoSmithKline plc, Johnson & Johnson, Merck & Co. Inc. and Pfizer Inc.
London, 28 May 2015: Technavio, an independent tech-focused global research firm, has announced the publication of its market research report on the infectious diseases market in the US 2015-2019. Emergence of IFN-free therapies is one of the key trends emerging in the market. Various healthcare providers are delaying therapies with the currently approved drugs in the anticipation of the launch of IFN-free regimens. The launch of these therapies is expected to increase the market sales of anti-viral drugs. The infectious diseases market in the US is expected to post a CAGR of 3.37% during the forecast period of 2014-2019.
Several factors such as increased patient population, growing public awareness, and the anticipated launch of IFN-free drugs are expected to propel market growth during the forecast period. The surge in infectious diseases results in the increased consumption of medicines. The launch of direct-acting anti-viral for treating viral infections also has a positive impact on market growth.
“DAAs increase the SVR and decrease the duration of hepatitis C therapies. The administration of these drugs also decreases the dosing frequency of IFN, thereby reducing the side effects associated with IFNs,” says Faisal Ghaus, Vice President of Technavio Research.
“An increased efficacy and a reduced dependence on IFN therapies have increased the overall effectiveness and uptake of hepatitis C anti-viral drug regimens.
To define the market conditions in the next 3-4 years, Technavio analysts have conducted in-depth analysis of the impact of market drivers, challenges and trends featuring data on product segmentations, vendor shares, growth rate by revenue and an evaluation of the different buying criteria in the order of importance.
https://www.technavio.com/%3Cp%3EIf%20you%20are%20interested%20in%20more%…
